抗苗勒管激素在早期乳腺癌化疗后卵巢功能诊断与预测中的价值
该研究基于OPTION试验数据,分析敏感自动化AMH检测对早期乳腺癌化疗后卵巢功能不全(POI)的诊断和预测准确性。结果显示,AMH低于检测限对24个月时POI诊断准确性良好(ROC AUC 0.86),在>40岁未接受戈舍瑞林女性中化疗结束时AMH预测POI的AUC为0.89。
要点
- AMH低于检测限可准确诊断化疗后24个月POI(AUC 0.86)。
- >40岁未用戈舍瑞林者化疗结束时AMH预测POI的AUC为0.89。
- FSH预测POI的AUC略低且特异性仅0.55。
核心结论
- 使用敏感AMH检测,>40岁早期乳腺癌患者化疗结束时AMH不可测可较好预测卵巢功能不会恢复。
研究设计与样本
- 基于OPTION试验(戈舍瑞林卵巢保护)中绝经前乳腺癌女性数据的事后分析。
- 诊断POI定义为闭经伴FSH升高,评估时间为诊断后24个月。
主要发现
- AMH低于检测限诊断24个月POI的ROC AUC为0.86(n=73),灵敏度1.0,特异性0.73。
- >40岁未接受戈舍瑞林女性化疗结束时AMH预测24个月POI的AUC为0.89(95%CI 0.75-1.0,n=32),灵敏度0.91,特异性0.82,DOR 42.8。
- FSH的AUC略低,特异性低至0.55。
- 年龄而非他莫昔芬影响AMH水平。
关键数值与推荐
- AMH低于检测限诊断POI:AUC 0.86,灵敏度1.0,特异性0.73(n=73)。
- >40岁未用戈舍瑞林者化疗结束时AMH预测POI:AUC 0.89(95%CI 0.75-1.0,n=32),灵敏度0.91,特异性0.82,DOR 42.8。
- FSH预测POI的AUC略低,特异性0.55。
临床怎么用
- 对>40岁早期乳腺癌患者,化疗结束时检测AMH有助于预测卵巢功能是否恢复。
- AMH不可测可能提示后续内分泌治疗策略可调整。
局限性
- 部分分析样本量较小(如预测分析n=32)。
- 研究基于OPTION试验数据,为事后分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Chemotherapy results in permanent loss of ovarian function in some premenopausal women. Accurate identification in women with hormone-sensitive early breast cancer (eBC) would allow optimisation of subsequent endocrine treatment. We sought to assess whether analysis of anti-Müllerian hormone (AMH) using a sensitive automated assay could identify women who would not regain ovarian function after chemotherapy. METHODS: Data from women in the Ovarian Protection Trial in Premenopausal Breast Cancer Patients (OPTION) trial of goserelin (a gonadotrophin-releasing hormone (GnRH) analogue) for ovarian protection were analysed. Women were assessed for premature ovarian insufficiency (POI: amenorrhoea with elevated follicle-stimulating hormone (FSH)) at 24 months after diagnosis. The accuracy of AMH for the diagnosis of POI and its prediction from measurement at the end of chemotherapy was calculated. RESULTS: AMH below the level of detection showed good diagnostic accuracy for POI at 24 months (n = 73) with receiver operating characteristic (ROC) area under the curve of 0.86, sensitivity 1.0 and specificity 0.73 at the assay limit of detection. In women aged >40 at diagnosis who did not receive goserelin, AMH measured at end of chemotherapy also gave good prediction of POI at 24 months (area under the curve (AUC) 0.89 95% CI 0.75-1.0, n = 32), with sensitivity 0.91, specificity 0.82, diagnostic odds ratio (DOR) 42.8. FSH gave slightly lower AUC, and specificity was low at 0.55. Age but not tamoxifen impacted on AMH levels. CONCLUSION: Using this sensitive AMH assay, the finding of an undetectable AMH level in women aged >40 at the end of chemotherapy for eBC gave a good prediction that ovarian function would not return. This may allow alterations in post-chemotherapy endocrine management.
引用
- Anderson RA, Mansi J, Coleman RE, et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017. PMID: 29117576. doi:10.1016/j.ejca.2017.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。